Aldeyra Therapeutics, Inc.

Listed Company

ALDXCIK 0001341235NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-33.80M

Total Assets

$72.06M

Equity

$44.25M

Shares Out

60.32M

Op. Cash Flow

$-33.35M

ALDX$1.68−66.60% · past yearDBEQ Basic

Daily closing prices

Business

Aldeyra Therapeutics is a biotechnology company discovering and developing pharmaceuticals that modulate reactive aldehyde species (RASP) to treat immune-mediated diseases. Its late-stage product candidates include reproxalap, a topical RASP modulator for dry eye disease and allergic conjunctivitis, and ADX-2191, an intravitreal methotrexate formulation for primary vitreoretinal lymphoma and retinitis pigmentosa. The company is advancing earlier-stage RASP modulators ADX-248 and ADX-246 for systemic immune-mediated conditions. Aldeyra operates through clinical development, contract manufacturing partnerships, and selective licensing arrangements, with no approved products currently marketed.

Summary from 10-K filed 2026-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	26	48	29	47	45
General and administrative	10	12	13	15	11
Loss from operations	−35	−60	−43	−63	−56
Interest income	3	6	7	2	185,363
Interest expense	−2	−2	−2	—	—
Total other income, net	1	4	5	655,351	−2
Net loss	−34	−56	−38	−62	−58
Net loss per share - basic	−0.56	−0.94	−0.64	−1.06	−1.07
Net loss per share - diluted	−0.56	−0.94	−0.64	−1.06	−1.07
Weighted average common shares outstanding - basic	60	59	59	58	54
Weighted average common shares outstanding - diluted	60	59	59	58	54

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	70	55	143	144	105
Marketable securities	0	47	0	30	0
Prepaid expenses and other current assets	2	3	5	7	3
Total current assets	72	104	148	181	233
Deferred offering costs	0	267,261	0	—	—
Right-of-use assets	275,861	266,955	510,814	249,265	351,863
Total assets	72	105	148	181	233
Accounts payable	158,461	180,453	1	133,625	1
Accrued expenses	6	12	6	14	11
Current portion of debt	15	31,372	15	911,763	—
Operating lease liabilities	280,537	271,631	239,183	249,265	229,607
Deferred collaboration revenue	6	6	0	—	—
Total current liabilities	28	19	22	15	12
Long-term debt, net of current portion	0	15	0	15	16
Total liabilities	28	34	29	30	27
Commitments and contingencies (Notes 3, 9, & 13)	—	—	—	—	—
Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued and outstanding	0	0	0	0	0
Common stock, voting, $0.001 par value; 150,000,000 authorized and 59,648,278 and 59,195,951 shares issued and outstanding, respectively	60,163	59,648	59,196	58,560	58,081
Additional paid-in capital	528	521	514	508	500
Accumulated other comprehensive income	0	37,442	0	−103,938	0
Accumulated deficit	−484	−450	−394	−357	−295
Total stockholders equity	44	71	120	151	206
Total liabilities and stockholders equity	72	105	148	181	233

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−34	−56	−38	−62	−58
Stock-based compensation	6	8	6	8	7
Non-cash interest expense	218,260	177,326	354,193	331,150	409,471
Net amortization of premium on marketable securities	−1	−2	−14,542	−47,245	0
Depreciation and amortization expense	251,993	249,623	262,780	258,707	264,180
Write-off of deferred offering costs	267,261	0	—	—	—
Prepaid expenses and other current assets	1	2	2	−4	2
Accounts payable	−21,992	−1	1	−886,077	638,064
Accrued expenses and other liabilities	−6	5	−8	1	5
Net cash used in operating activities	−33	−43	−30	−57	−43
Purchases of marketable securities	−40	−97	0	−93	0
Maturities of marketable securities	88	52	30	63	0
Net cash provided by (used in) investing activities	48	−45	30	−30	−7,806
Issuance costs	0	−267,261	0	—	—
Proceeds from exercise of stock options	1	350,279	194,129	1	5
Proceeds from employee stock purchase plan	19,616	38,060	111,102	96,665	61,529
Debt end of term charge paid in cash	0	−292,500	−1	0	—
Net cash provided by (used in) financing activities	1	−171,422	−1	1	194
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	16	−88	−2	−85	152
Cash paid during the period for interest	2	2	2	1	1

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Aldeyra Therapeutics, Inc.'s CIK number?

Aldeyra Therapeutics, Inc.'s SEC CIK number is 0001341235 (1341235). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Aldeyra Therapeutics, Inc.'s SEC filings?

All of Aldeyra Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

Look up any company's CIK number →